6-K 1 d443575d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2023

Commission File Number: 001-41562

 

 

NewAmsterdam Pharma Company N.V.

(Exact name of registrant as specified in its charter)

 

 

Gooimeer 2-35

1411 DC Naarden

The Netherlands

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

On June 3, 2023, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing data from its Phase 2 ROSE2 trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy. A copy of the press release is furnished as 99.1 to this Report on Form 6-K.

On June 5, 2023, the Company issued a press release announcing topline results from its Phase 2b dose-finding trial evaluating obicetrapib in Japanese patients. A copy of the press release is furnished as Exhibit 99.2 hereto.

A copy of the Company’s most recent corporate presentation is furnished as Exhibit 99.3 to this Report on Form 6-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    NewAmsterdam Pharma Company N.V.
June 5, 2023     By:  

/s/ Michael Davidson

     

Name: Michael Davidson

Title: Chief Executive Officer